CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The New Medicine for Trypanosomatid Infections project focuses on developing new drug candidates to combat diseases caused by Trypanosomatidae parasites, such as sleeping sickness and Chagas disease. By optimizing existing compounds and utilizing a collaborative drug discovery platform, the project aims to enhance trea…
The infectious diseases burden imposed by the parasites of Trypanosomatidae family represents a huge problem on people’s lives in countries where these diseases are endemic.
Problems associated with existing drugs include inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance.
New drugs are urgently needed now and in the foreseeable future.
The New Medicine for Trypanosomatid Infections (NMTrypI) consortium uses a highly interdisciplinary approach to optimize p…
UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Hamburg
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC
Portugal, Porto
Type: Research institute
Activity type: Research Organisations
SME: No
Italy, Siena
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
